# Bloom Burton & Co.

> Bloom Burton & Co. is a VC fund backing Health Care and Biotechnology. See 7 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: Toronto, Canada
- Total investments: 7
- Last investment: May 2025
- Lead investor: 71%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/company/bloom-burton-&-co-/
- Website: https://x.com/bloomburton

Bloom Burton & Co. is an investment banking firm that provides financial advisory services for its clients.

## Contacts

5 contacts available for Bloom Burton & Co.. Shizune tracks 3 team members at Bloom Burton & Co.. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/bloom-burton-co-?utm_source=investor_profile

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Health Care | 5 | 71% |
| Biotechnology | 2 | 29% |
| B2B | 1 | 14% |
| Medical | 1 | 14% |
| Genetics | 1 | 14% |

11 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series A | 2 | 29% |
| Post-IPO Debt | 2 | 29% |
| Post-IPO Equity | 2 | 29% |

### Country

| Country | Investments | Share |
| --- | --- | --- |
| Canada | 4 | 57% |
| United States | 1 | 14% |

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Armand Balboni | Partner/Director | 0 | — |
| Brian Bloom | Co-Founder, Chairman and CEO | 0 | — |
| Jamie Doran | Consultant, Drug Development | 0 | — |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Satellos Bioscience | Satellos Bioscience is a private regenerative medicine company developing novel therapeutics that stimulate or restore muscle regeneration. The company's programs focus on developing an oral therapeutic drug for Duchenne muscular dystrophy that serves to correct this dysregulation. | $1.2M | Post-IPO Equity | May 20, 2025 |  |
| Newtopia | Newtopia is a personalized health company - leveraging personal genetics and the latest engagement science - to solve a big problem: our unhealthy lifestyles are killing us, and costing corporations a fortune.Whether obesity, chronic disease, or aging, these all have roots in our lifestyle behaviors and there is no improvement in sight.It’s an absolutely massive market in a perfect storm for disruption - both individuals and corporations are looking - and willing to spend - on solutions but existing providers are failing to provide sustainable solutions. The result - our lifestyles are having giant economic and social consequences.Newtopia’s patented solution to the problem is the invention of a unique health engagement platform. What is a health engagement platform? We inspire people to make the right lifestyle decisions to stay healthy.With a proven $2-$3 per day model, an 80% success rate with beta clients, and early success selling and delivering results to large corporations and insurers, Newtopia is the perfect B2B partner. Newtopia's opportunity to scale comes through partnering with insurers, self-insured employers and brands to deliver sustainable health outcomes and a meaningful ROI. | $148.1K | Post-IPO Debt | Sep 04, 2024 |  |
| Appili Therapeutics | Appili Therapeutics is an anti-infective pharmaceutical development company. Our approach lies in matching unmet medical needs with opportunities for more effective solutions that range from improvements in established therapies to entirely new classes of anti-infectives. | $292.4K | Post-IPO Debt | Apr 26, 2024 |  |
| Appili Therapeutics | Appili Therapeutics is an anti-infective pharmaceutical development company. Our approach lies in matching unmet medical needs with opportunities for more effective solutions that range from improvements in established therapies to entirely new classes of anti-infectives. | $226.4K | Post-IPO Debt | Jun 29, 2023 |  |
| AceAge | AceAge is a healthcare technology company, creating intuitive products to ease the aging process and improve health outcomes.AceAge is the company behind the next innovation in healthcare technology. Its upcoming product is a home health appliance designed to help people take their medication properly. Karie is a personal health companion thatorganizes, schedules, and dispenses pills with easy one-button control. The CEO of AceAge, Spencer Waugh, created Karie to increase the health and safety of medical patients, and as a way to minimize the negative consequences of missed medications or general failure to adhere to medication directions. The success of medicine is dependent on the patient’s compliance with the medical directions that accompany it, making it an integral part of healthcare. The total direct and indirect costs of nonadherence in the US annually is $290 billion. By making daily medicine routines completely automated, Karie removes the chance of human error. Karie uses common multi-dose pouch packaging that can be pre-set by pharmacists. Doses are scheduled, delivered and monitored for the user. Karie is easy to use, enables greater patient autonomy and ensures better healthcare through a highly coordinated program. | $3.9M | Series A | Dec 03, 2020 |  |
| Triumvira Immunologics | Triumvira Immunologics, Inc. (“Triumvira”) is an immunotherapy company co-founded in 2015 by Dr. Jonathan Bramson at McMaster University and Bloom Burton & Co., with the vision of developing novel T cell therapies that are safer and more efficacious than current cancer treatments, including chimeric antigen receptor (CAR) and engineered T cellreceptor (TCR) therapies. Their proprietary T cell Antigen Coupler (TAC) technology recruits the entire natural T cell receptor and is independent of the major histocompatibility complex (MHC), allowing for the development of better therapies for a broader range of patients with solid or liquid malignancies and also with diseases other than cancer. | $55M | Series A | Aug 27, 2020 |  |
| Appili Therapeutics | Appili Therapeutics is an anti-infective pharmaceutical development company. Our approach lies in matching unmet medical needs with opportunities for more effective solutions that range from improvements in established therapies to entirely new classes of anti-infectives. | $12.7M | Post-IPO Equity | Jun 10, 2020 |  |

7 of 7 investments shown.

## Co-investors
- [Leaps by Bayer](https://shizune.co/investors/profile/leaps-by-bayer) — VC Fund, 2 deals together
- [Centre for Commercialization of Cancer Immunotherapy](https://shizune.co/investors/profile/centre-for-commercialization-of-cancer-immunotherapy) — VC Fund, 1 deal together
- [Haywood Securities Inc.](https://shizune.co/investors/profile/haywood-securities-inc) — VC Fund, 1 deal together
- [Industrial Alliance Securities](https://shizune.co/investors/profile/industrial-alliance-securities-inc) — VC Fund, 1 deal together
- [Longliv Ventures](https://shizune.co/investors/profile/longliv-ventures) — VC Fund, 1 deal together
- Mackie Research Capital Corporation — VC Fund, 1 deal together

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

## FAQ

### What does Bloom Burton & Co. invest in?

Bloom Burton & Co. invests primarily in Health Care, Biotechnology and B2B startups, most often at Series A and Post-IPO Debt stage. Most of the 7 investments tracked by Shizune back companies in Canada. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### How do I contact Bloom Burton & Co.?

Public channels for Bloom Burton & Co. include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at Bloom Burton & Co.?

The team at Bloom Burton & Co. includes Armand Balboni (Partner/Director), Brian Bloom (Co-Founder, Chairman and CEO) and Jamie Doran (Consultant, Drug Development). The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co